AI in Medicine News ・ 💊 Drug discovery and clinical trials

Healthcare ETF: China May Control a Key Bottleneck in AI Drug Discovery

KraneShares · 10/21 20:26 UTC

AI drug discovery is moving from a software story to a physical-capacity story, and a large share of that capacity sits in China. Before AI transforms drug discovery, it may strain the infrastructure used to test molecules worldwide. China's biotech services sector represents one of the largest pools of that infrastructure.

Read the original (KraneShares)

See it in the digest → ・ See this issue →